Christelle Kerrien-Boglione

Rennes, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Can pharmacokinetic/pharmacodynamic targets be achieved with voriconazole in the treatment of urinary tract infections caused by Candida spp. with reduced susceptibility to fluconazole?

Can pharmacokinetic/pharmacodynamic targets be achieved with voriconazole in the treatment of urinary tract infections caused by Candida spp. with reduced susceptibility to fluconazole?

Journal: The Journal of antimicrobial chemotherapy

Published: October 23, 2025

Unravelling Voriconazole's Hepatic Metabolism: A Narrative Review on Factors Impacting Voriconazole-N-Oxide Exposure.

Unravelling Voriconazole's Hepatic Metabolism: A Narrative Review on Factors Impacting Voriconazole-N-Oxide Exposure.

Journal: Mycoses

Published: July 28, 2025

Managing High-Risk Drug Interactions With Nirmatrelvir/Ritonavir: Experience From a Dedicated Pharmacology Advice Service.

Managing High-Risk Drug Interactions With Nirmatrelvir/Ritonavir: Experience From a Dedicated Pharmacology Advice Service.

Journal: Clinical and translational science

Published: July 15, 2025

Biliary diffusion and antifungal activity of caspofungin and fluconazole in liver transplant recipients: A pilot study.

Biliary diffusion and antifungal activity of caspofungin and fluconazole in liver transplant recipients: A pilot study.

Journal: Journal de mycologie medicale

Published: June 19, 2024

Voriconazole as an alternative oral treatment in fluconazole-resistant urinary candidiasis.

Voriconazole as an alternative oral treatment in fluconazole-resistant urinary candidiasis.

Journal: Infectious diseases now

Published: April 19, 2024

A biological pharmacology network to secure the risk of drug-drug interaction with nirmatrelvir/ritonavir.

A biological pharmacology network to secure the risk of drug-drug interaction with nirmatrelvir/ritonavir.

Journal: Therapie

Published: March 14, 2024

Can we predict the influence of inflammation on voriconazole exposure? An overview.

Can we predict the influence of inflammation on voriconazole exposure? An overview.

Journal: The Journal of antimicrobial chemotherapy

Published: October 05, 2023

Contribution of voriconazole N-oxide plasma concentration measurements to voriconazole therapeutic drug monitoring in patients with invasive fungal infection.

Contribution of voriconazole N-oxide plasma concentration measurements to voriconazole therapeutic drug monitoring in patients with invasive fungal infection.

Journal: Mycoses

Published: October 04, 2022

Influenza- and COVID-19-Associated Pulmonary Aspergillosis: Are the Pictures Different?

Influenza- and COVID-19-Associated Pulmonary Aspergillosis: Are the Pictures Different?

Journal: Journal of fungi (Basel, Switzerland)

Published: April 14, 2021

Toward the personalized and integrative management of voriconazole dosing during COVID-19-associated pulmonary aspergillosis.

Toward the personalized and integrative management of voriconazole dosing during COVID-19-associated pulmonary aspergillosis.

Journal: Critical care (London, England)

Published: February 01, 2021

Using unusual drug-drug interactions to maximize voriconazole treatment efficacy.

Using unusual drug-drug interactions to maximize voriconazole treatment efficacy.

Journal: Medecine et maladies infectieuses

Published: November 13, 2018

Vancomycin immunoassay: does the Advia Centaur XPT underestimate the exposure of patients? A method comparison study.

Vancomycin immunoassay: does the Advia Centaur XPT underestimate the exposure of patients? A method comparison study.

Journal: Clinical chemistry and laboratory medicine

Published: October 01, 2018

Showing 1-12 of 18

Last Updated: 09/26/2026